Issues‎ > ‎vol1n1‎ > ‎

jsmc-10012


PREVALENCE OF METABOLIC SYNDROME AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS IN DUHOK


Zana Sidiq Mohammed Saleem *and Hama Najm Jaf**


* School of Medicine, Faculty of Medical Sciences, University of Duhok. Duhok Dialysis and Transplantation Center. 
** Head Kurdistan Board for Medical Specializations.


Submitted: 10/4/2011; Accepted: 14/9/2011Published 1/12/2011


ABSTRACT


Background 

The  metabolic  syndrome  is  a  constellation  of  risk  factors  of  metabolic  origin  that  are  accompanied  by increased risk for cardiovascular disease and type 2 diabetes. These risk factors are atherogenic dyslipidemia, elevated  blood  pressure,  elevated  plasma  glucose,  a  prothrombotic  state,  and  a  proinflammatory state. Metabolic  syndrome  is associated with overall mortality; with cardiovascular mortality  in particular;  it has been  shown  that  metabolic  syndrome  is  an  independent  clinical  indicator  of  macro-  and  microvascular complications in diabetics. 

Objective 

The objective of this study was to estimate the prevalence and characteristics of metabolic syndrome among type-2 diabetic patients in Duhok Governorate.

Materials and Methods 

This study involved 394 randomly selected patients from those suffering from type-2 diabetes mellitus, from 1st  February  through  30th June  2009  and who were attending Duhok Diabetic  Center. The  patients were interviewed and examined, and  their  lipid profiles and  fasting blood  sugar were checked 12 hours after an
overnight  fasting. Metabolic  syndrome was  defined  according  to  the  criteria  of  the National  Cholesterol Education Program Adult Treatment Panel III. 

Results 

Three hundred ninety four patients (males 33%, females 67 %) were screened and their mean age was (52 ± 8) years, 77% of participants were found to have metabolic syndrome. Metabolic syndrome was more among females  (89%),  those with high  fasting blood glucose  (93%),  those with high waist circumference (80%), those  with  high  triglyceride  (72%),  those  with  low  high  density  lipoprotein  (90%),  high  blood  pressure (68%), and those who lacked physical activities. .

Conclusion 

A  comprehensive  protocol  for  management  of  diabetic  patients  needs  to  be  adopted  involving  not  only control of blood sugar but also other risk factors like obesity, high blood pressure and dyslipidemia.


KEYWORDS

 Metabolic Syndrome, Type 2 Diabetes Mellitus, Duhok

References 

1. Hauner H. Insulin resistance and the metabolic syndrome- a challenge of the new millennium. Eur J Clin Nutr 2002; 56 (1): 24-9.

2. Pasqui A, Puccetti M , Di Renzo M, Brunii F, Camarri A, Palazzuoli A. Structural and functional abnormality of systemic microvessels in cardiac syndrome X. Nutr Metab Cardiovasc Dis 2005; 15(1): 56-64.

3. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Croos-sectional data from the Bruneck study.  Int J Obes 2003; 27: 1283-9.

4. Kim WY, Kim JE, Choi YJ, Huh KB. Nutritional risk and metabolic syndrome in Korean type 2 diabetes mellitus. Asia Pac J Clin Nutr 2008; 17:47-51.

5. Marchesini G, Forlani G, Cerrelli F, MManini R, Natale S, Baraldi L, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 2004; 2: 383-90.

6. Grundy SM, Cleeman JI, Daniels SR, Karen A, Doralo KA, Eckel RH, et al. Diagnosis and management of the metabolic syndrome - an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement: executive summary. Circulation 2005;112; 2735-52.

7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The lancet 2005; 365(9465):114-28.

8. Eckel RH. The metabolic syndrome. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al, editors. Harrison's principle of internal medicine. 17th ed. New York, NY: The McGraw-Hill Companies Inc.; 2008. p. 1509-14.

9. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3(2): 463-524.

10. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108(12): 1527-32.

11. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clinical Endocrinol Metab 2004; 89(6):2601–7

12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421.

13. William E, Krauss WE, Huamard JA, Duscha BD, Knetzger KJ, Wharton MB. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347(19): 1483-92.

14. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368 (9536): 646-58.

15. Kotchen TA. Hypertensive vascular disease. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al, editors. Harrison's principle of internal medicine. 17th ed. New York, NY: The McGraw-Hill Companies Inc.; 2008. p. 1554-62.

16. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guideline. Circulation 2004; 110: 227-39.

17. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81(4A): 13B-17B.

18. Ashraf SMS, Ziauddin F, Jahangeer U. Metabolic syndrome in type2 diabetes mellitus. Pak J Med Sci 2006; 22(3): 295-9.

19. Janghorbani M, Amini M. Metabolic syndrome in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. Metab Syndr Relat Disord 2007; 5(3):243-54.

20. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 1998; 47:1643-9.

21. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999; 245:163-74.

22. Alshkri MM, Elmehdawi RR. Metabolic syndrome among type-2 diabetic patients in Benghazi-Libya: a pilot study. Libyan J Med 2008; 3:177-80.

23. Ahmed AM, Salem Bin Selm S. Prevalence of metabolic syndrome among patients with type 2 diabetes in Aden governorate. MEJFM 2009; 7(6):15-7